Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2022 08:35 ET | Source: PalisadeBio

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
August 16, 2022 16:05 ET | Source: PalisadeBio

Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option

CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
August 15, 2022 09:00 ET | Source: PalisadeBio

Palisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
August 12, 2022 08:30 ET | Source: PalisadeBio

Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
August 01, 2022 08:05 ET | Source: PalisadeBio

Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
July 27, 2022 08:05 ET | Source: PalisadeBio

Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
June 29, 2022 08:30 ET | Source: PalisadeBio

Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of...
June 07, 2022 08:30 ET | Source: PalisadeBio

Palisade Bio to Present at the 2022 BIO International Convention

CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
May 13, 2022 09:00 ET | Source: PalisadeBio

Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal...
May 10, 2022 17:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires

CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications,...